We are monitoring the impact of COVID-19 on Europe Ovarian Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1393
Share on
Share on

Europe Ovarian Cancer Therapeutics Market By Stage Of Cancer (Stage I, Stage II, Stage III, Stage IV), By Cancer Type (Primary Peritoneal Carcinoma, Ovarian Stromal Tumors, Ovarian Germ Cell Tumors, Epithelial Ovarian Tumors), By Diagnosis (Physical Examination, Blood Tests, Ultrasound, PET, CT Scan, MRI, Human Chorionic Gonadotropin Test, Biopsy), By Type Of Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy, Targeted Therapy), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: February, 2020
ID: 1393
Pages: 181

Europe Ovarian Cancer Therapeutics Market was worth $XX billion in 2018 and estimated to reach $XX billion by the end of 2023 with a CAGR of XX%. Ovarian cancer occurs when cell growth in the ovarian tissue becomes uncontrollable. Ovarian cancer is one of the most common causes of death in women across the world. There is a need for development of new medication and therapies for the proper treatment of this ailment, and newer techniques for the timely diagnosis of ovarian cancer. Hence, the market for ovarian cancer therapeutics has a great potential.

The treatment of ovarian cancer is done depending on the stage the disease is in. The treatment includes surgery, radiation, chemotherapy, and biological therapy. It is also known that ovarian cancer is the most chemo-sensitive cancer. Chemotherapy treatment is more effective when combined with radiation therapy.

Cases of ovarian cancer have grown rapidly, as a result, so has its Europe therapeutics market. One of the factors is increase in aging of the women population. Introduction of new drugs and effective therapies, increase in people’s disposable income, and better government funding and support are some of the key factors behind the growth of global ovarian cancer market. Additionally, increasing awareness about healthcare is also propelling the growth of the ovarian cancer market. Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of the key factors restraining the growth for ovarian cancer market.

The Europe ovarian cancer market is segmented based on the stage of cancer as Stage I, Stage II, Stage III and Stage IV. Stages of cancer are further sub-segmented into Stage IA, Stage IB, Stage IC, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB and Stage IIIC. By cancer type, it is segmented into Primary Peritoneal Carcinoma, Ovarian Stromal Tumors, Ovarian Germ Cell Tumors and Epithelial Ovarian Tumors. By Diagnosis, it is further segmented into Physical Examination, Blood Tests, Ultrasound, PET, CT Scan, MRI, Human Chorionic Gonadotropin Test and Biopsy, By type of treatment, it is segmented into Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy and Targeted Therapy. Futhermore, on the basis of geography, the Europe market is analysed under various regions namely UK, Spain, Italy, Germany and France. North American region, in particular, US is the largest market for Ovarian cancer. Europe is the second largest market as the cases of ovarian cancer are very high too.

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc.       

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Stage Of Cancer                        

                                5.1.1 Stage I       

                                                5.1.1.1 Stage IA

                                                5.1.1.2 Stage IB

                                                5.1.1.3 Stage IC

                                5.1.2 Stage II     

                                                5.1.2.1 Stage IIA

                                                5.1.2.2 Stage IIB

                                                5.1.2.3 Stage IIC

                                5.1.3 Stage III    

                                                5.1.3.1 Stage IIIA

                                                5.1.3.2 Stage IIIB

                                                5.1.3.3 Stage IIIC

                                5.1.4 Stage IV    

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer               

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Primary Peritoneal Carcinoma        

                                5.2.3 Ovarian Stromal Tumors   

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type      

                                5.2.7 Market Attractiveness Analysis, By Type     

                                5.2.8 Market Share Analysis, By Type      

                5.3 Diagnosis                     

                                5.3.1 Introduction           

                                5.3.2 Physical Examination          

                                5.3.3 Blood Tests             

                                5.3.4 Ultrasound             

                                5.3.5 PET             

                                5.3.6 CT Scan     

                                5.3.7 MRI            

                                5.3.8 Human Chorionic Gonadotropin Test          

                                5.3.9 Biopsy       

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis          

                                5.3.11 Market Attractiveness Analysis, By Diagnosis         

                                5.3.12 Market Share Analysis, By Diagnosis          

                5.4 Treatment                  

                                5.4.1 Introduction           

                                5.4.2 Chemotherapy     

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy              

                                5.4.5 Surgery    

                                5.4.6 Immunotherapy   

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment          

                                5.4.9 Market Attractiveness Analysis, By Treatment         

                                5.4.10 Market Share Analysis, By Treatment       

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.3.2 By Stage of Cancer

                                                6.1.3.3 By Type

                                                6.1.3.4 By Diagnosis

                                                6.1.3.5 By Treatment

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Aetera Zenteris Inc.                

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Eli Lilly and Company                             

                8.3 Roche                           

                8.4 Amgen                         

                8.5 Janssen Pharmaceuticals, Inc.                             

                8.6 Bristol Myers Squibb Company                          

                8.7 Novogen, Inc.                            

                8.8 GlaxoSmithKline                      

                8.9 Boehringer Ingelheim                            

                8.10 AstraZeneca                            

                8.11 Genentech Inc.                       

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  2. Europe Stage I Market By Region, From 2018-2023 ( USD Million )
  3. Europe Stage II Market By Region, From 2018-2023 ( USD Million )
  4. Europe Stage III Market By Region, From 2018-2023 ( USD Million )
  5. Europe Stage IV Market By Region, From 2018-2023 ( USD Million )
  6. Europe Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  7. Europe Primary Peritoneal Carcinoma Market By Region, From 2018-2023 ( USD Million )
  8. Europe Ovarian Stromal Tumors Market By Region, From 2018-2023 ( USD Million )
  9. Europe Ovarian Germ Cell Tumors Market By Region, From 2018-2023 ( USD Million )
  10. Europe Epithelial Ovarian Tumors Market By Region, From 2018-2023 ( USD Million )
  11. Europe Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  12. Europe Physical Examination Market By Region, From 2018-2023 ( USD Million )
  13. Europe Blood Tests Market By Region, From 2018-2023 ( USD Million )
  14. Europe Ultrasound Market By Region, From 2018-2023 ( USD Million )
  15. Europe PET Market By Region, From 2018-2023 ( USD Million )
  16. Europe CT Scan Market By Region, From 2018-2023 ( USD Million )
  17. Europe MRI Market By Region, From 2018-2023 ( USD Million )
  18. Europe Human Chorionic Gonadotropin Test Market By Region, From 2018-2023 ( USD Million )
  19. Europe Biopsy Market By Region, From 2018-2023 ( USD Million )
  20. Europe Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  21. Europe Chemotherapy Market By Region, From 2018-2023 ( USD Million )
  22. Europe Radiation Therapy Market By Region, From 2018-2023 ( USD Million )
  23. Europe Hormonal Therapy Market By Region, From 2018-2023 ( USD Million )
  24. Europe Surgery Market By Region, From 2018-2023 ( USD Million )
  25. Europe Immunotherapy Market By Region, From 2018-2023 ( USD Million )
  26. Europe Targeted Therapy Market By Region, From 2018-2023 ( USD Million )
  27. U.K. Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  28. U.K. Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  29. U.K. Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  30. U.K. Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  31. Germany Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  32. Germany Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  33. Germany Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  34. Germany Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  35. France Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  36. France Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  37. France Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  38. France Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  39. Italy Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  40. Italy Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  41. Italy Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  42. Italy Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  43. Spain Ovarian Cancer Therapeutics Market By Stage Of Cancer, From 2018-2023 ( USD Million )
  44. Spain Ovarian Cancer Therapeutics Market By Cancer Type, From 2018-2023 ( USD Million )
  45. Spain Ovarian Cancer Therapeutics Market By Diagnosis, From 2018-2023 ( USD Million )
  46. Spain Ovarian Cancer Therapeutics Market By Type Of Treatment, From 2018-2023 ( USD Million )
  47. Europe Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  48. Europe Stage IA Market By Region, From 2018-2023 ( USD Million )
  49. Europe Stage IB Market By Region, From 2018-2023 ( USD Million )
  50. Europe Stage IC Market By Region, From 2018-2023 ( USD Million )
  51. U.K. Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  52. Germany Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  53. France Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  54. Italy Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  55. Spain Blood Glucose Monitoring Market By Stage I, From 2018-2023 ( USD Million )
  56. Europe Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  57. Europe Stage IIA Market By Region, From 2018-2023 ( USD Million )
  58. Europe Stage IIB Market By Region, From 2018-2023 ( USD Million )
  59. Europe Stage IIC Market By Region, From 2018-2023 ( USD Million )
  60. U.K. Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  61. Germany Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  62. France Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  63. Italy Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  64. Spain Blood Glucose Monitoring Market By Stage II, From 2018-2023 ( USD Million )
  65. Europe Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )
  66. Europe Stage IIIA Market By Region, From 2018-2023 ( USD Million )
  67. Europe Stage IIIB Market By Region, From 2018-2023 ( USD Million )
  68. Europe Stage IIIC Market By Region, From 2018-2023 ( USD Million )
  69. U.K. Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )
  70. Germany Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )
  71. France Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )
  72. Italy Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )
  73. Spain Blood Glucose Monitoring Market By Stage III, From 2018-2023 ( USD Million )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample